PolleyMed, LLC - 726018 - 05/14/2026

Why It Matters

The enforcement highlights regulatory risks for companies selling health‑related devices that make drug‑like claims, potentially exposing them to legal penalties and market removal. It underscores the FDA’s focus on preventing unapproved products from reaching consumers, especially amid heightened public health concerns.

Key Takeaways

• SaniiSwab labeled as drug for nasal infection prevention
• FDA cites unapproved new drug status under FD&C Act
• Website claims FDA OTC approval, violating misbranding rules
• Company must respond within 15 business days with corrective plan

Pulse Analysis

The FDA’s warning letter to PolleyMed illustrates how aggressively the agency polices products that blur the line between medical devices and drugs. By positioning SaniiSwab™ as a nasal disinfectant that can prevent a range of pathogens—including COVID‑19 and influenza—the company invoked language that triggers the definition of a drug under section 201(g)(1) of the FD&C Act. This classification demands a formal New Drug Application, a step PolleyMed has not taken, rendering the product an unapproved new drug and subject to immediate enforcement action.

Misbranding concerns further compound the compliance breach. PolleyMed’s website and marketing materials explicitly state the product is “FDA OTC approved,” a claim that is false without an authorized over‑the‑counter monograph. Under section 502(a), such misleading statements constitute a misbranded drug, exposing the firm to civil penalties and potential product seizure. The warning letter also notes that the product’s intended nasal route falls outside the scope of the existing OTC Antiseptic Monograph, which only covers topical skin applications.

For businesses operating in the health‑care space, this case serves as a cautionary tale about the importance of rigorous regulatory review before launching consumer‑facing claims. Companies must ensure that any health‑related assertions are supported by FDA‑approved pathways, whether through a New Drug Application, an OTC monograph, or a cleared medical device designation. Failure to do so not only risks enforcement letters but can also erode consumer trust and attract costly litigation. Proactive compliance, transparent labeling, and prompt response to FDA inquiries are essential to maintaining market access and protecting public health.